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1 
EXECUTIVE SUMMARY 
Engineering Biology seeks to apply engineering principles to design, modify, and 
produce customized biological components and systems. The recent advent of tools 
such as the CRISPR/Cas9 system for gene editing and gene regulation has sharply 
accelerated development in this exciting field. However, several challenges need to be 
addressed in order to transition laboratory-scale results to commercial-scale solutions.  
This report identifies emerging platform technologies that, if matured, will accelerate the 
growth in the rapidly changing field of Engineering Biology. The conclusions in the 
report are intended to guide stakeholders from government, industry and academia as 
they seek to further develop innovations in this field. 
In order to gain the most up-to-date perspective on emerging technologies in 
Engineering Biology, MForesight convened panel of industry-based subject matter 
experts. The panel evaluated a range of pre-competitive, emerging platform 
technologies and assigned a development priority to one technology and several 
enabling development tools based on several specific selection criteria:  
• The platform technologies must be cross-cutting, with broad applications across 
the engineering biology industry. 
• The maturity of the technologies must be suitable for both private industry and 
government to consider investing in further development. 
• The new technologies should increase the likelihood that the technology will give 
the U.S. a first-mover advantage in the marketplace. 
The technologies that clearly met the selection criteria include: 
• The key platform technology—Standardized Verified and Tractable Host Cells or 
Strains for Biomanufacturing—will provide industries with host cells and strains 
that are amenable to engineering for scale-up or scale-out. The standardized and 
verified nature of these hosts will streamline regulatory processes and 
significantly de-risk aspects of the biomanufacturing process.   
• Several enabling tools are needed to fully realize the potential offered by the 
development of tractable host cells or strains. These tools will also enable more 
rapid Design-Build-Test-Learn (DBTL) cycles, which is critical for the 
development of new host cells or strains. These tools include:  
(i) High Throughput Omics;  
(ii) Low-Cost and Error Free DNA Elements and DNA Assembly; and  
(iii) Efficient, Host-Neutral Gene Editing.  
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SUMMARY OF KEY OBSERVATIONS 
o Pre-competitive and core technology development should be kept as open as 
possible in order to sustain the network effect gained from using standard biological 
platforms, data systems, and testing/manufacturing standards. 
o Intellectual property (IP) generated through publicly-funded development should be 
made widely available.  
o The high cost of clinical trials is pushing investors away from smaller markets. 
Additional cost is incurred when substantial human data is required prior to 
investment in definitive clinical trials.  
o The burden of bridging the gap from animal models to exploratory human studies 
can be de-risked via transitional funding from government sources. 
o Standards and reference materials lag behind the rapid pace of change within this 
industry. Regulatory agency personnel should be embedded with technology 
creators during the development process in order to collaboratively establish 
effective and appropriate regulations.    
o Many university technology transfer offices underestimate the complexities of 
maturing a technology into a market-ready state and personnel may overvalue early-
stage discoveries. To arrive at more accurate valuations, universities could seek a 
better understanding of the true cost of scaling and process development.  
o Modeling for predictive scaling is needed to inform organism design and is a critical 
aspect of de-risking technologies for industrial adoption. 
o Biosafety/bioterrorism concerns are driving calls for increased oversight of such 
tools or even equipment.1 Collaboration between government agencies and industry-
experts will result in technically sound solutions that can be effectively implemented.   
o Science-based advocacy is needed to address public concerns regarding genetically 
modified organisms (GMOs).2  
o Significant on-the-job training for new biotech employees is often needed to help 
them master the core concepts of biomanufacturing. To better prepare students for 
                                            
1 An additional challenge in biosafety/bioterrorism is the fundamental question of how to clearly and 
unambiguously define a taxonomic name (e.g. pathogen X or toxin Y) for insertion into legislation. With 
few exceptions, current regulations do not enumerate genes or gene sequences in spite of the fact that all 
of modern biology deals with specific sequence descriptions based on A, T, C, G. This has resulted in a 
fundamental gap in converting well-defined sequences of concern into regulatory lists. 
2  Genetically Modified Organisms (GMOs) are living organisms that have had their intrinsic genetic 
material modified using genetic engineering technology. 
 
  
 
 
 
3 
jobs requiring high-levels of technical knowledge, universities should consider 
creating new undergraduate and master’s degree programs specifically targeted 
towards biomanufacturing.  
o Practical, hands-on training at the internship and apprenticeship level will fill an 
important gap in the current workforce. 
o The U.S. does not have a roadmap or national strategy in the area of Engineering 
Biology to help identify sectors for investment. (The Engineering Biology community 
in the UK is well-organized and has strong support from the government).3 
 
                                            
3 Research Councils UK. A Synthetic Biology Roadmap for the UK. July 2012.  
http://www.rcuk.ac.uk/publications/reports/syntheticbiologyroadmap/  
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INTRODUCTION 
For centuries, humans have been altering the genetic material of living organisms 
through selective breeding. Yet, today, these old practices are taking on fundamentally 
new meaning and consequence. Scientists are creating new DNA sequences from 
scratch in order to produce materials with potential to solve practical problems in 
diverse fields from medical treatment to energy production. By applying engineering 
principles to design, modify, and produce customized biological components and 
systems, the field of Engineering Biology is rapidly changing how biological systems can 
be used. The potential benefits of Engineering Biology — from low-emissions biofuels to 
new cancer-fighting medical technologies — are enormous. But so are the potential 
pitfalls. 
Venturing into a field with extraordinary tools and unprecedented implications — altering 
the building blocks of life itself — requires skillful measures to identify and address 
potential unintended consequences. Governing the growth of Engineering Biology 
means not only maximizing efforts to enable discovery and invention to create jobs and 
meet crucial human needs; it also means thinking in interdisciplinary ways about 
unforeseen implications for health, safety, the environment, and the economy in the 
long-range future. 
With the rise of Engineering Biology, U.S. firms are finding that they must invest 
strategically in new technology if they wish to assume the “first-mover advantage” and 
bring meaningful innovations from the laboratory to the marketplace. Identifying and 
prioritizing emerging technologies increasingly depends on a strong collaboration 
between those firms, U.S. universities and federal agencies.   
BACKGROUND ON ENGINEERING BIOLOGY 
The current state-of-the-art in Engineering Biology can be best described as artisanal, 
where each company follows their own pathway in the classic Design-Build-Test-Learn 
(DBTL) development cycle to design and scale-up new products. Given the high 
inherent cost of biotechnology development (the cost for a new bioproduct can be in the 
hundreds of millions of dollars 4 ), the aggregated cost of duplicated effort across 
companies in the industry is substantial. The high development cost also represents a 
substantial barrier-to-entry that precludes many entrepreneurs and investors from 
starting Engineering Biology-based companies, which dampens further growth in this 
nascent bioeconomy. 
                                            
4 The development cost for semi-synthetic artemisinin (an antimalarial drug) is estimated by UC Berkeley 
researchers to be in the range of $130M. 
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This environment is ideal for a public-private partnership (PPP) on platform 
development of key pre-competitive technologies. 5  A PPP can benefit from 
standardized software, standardized processes, and can also accelerate development 
by sharing information on successes/failures with other members of the partnership. 
Biotechnology platform technologies in the pre-competitive space can provide a 
leveraging mechanism so that all companies can benefit from pooled resources.  
By moving past basic laboratory research into the translational research area, 
Engineering Biology innovations can be matured toward their use in commercial 
settings. An important step is to develop translational tools and technology to automate 
and scale-up the processing of synthesized DNA. In addition, a new generation of 
workers will require training in the critical skills needed to operate bio-factories safely 
and cost-effectively. Rapid, cost-effective DNA synthesis will ultimately be able to 
develop transgenic or synthetic chromosomes for use in areas as diverse as agriculture, 
health care, and natural products. 
Recent reports from the National Academies of Sciences, 6  OSTP Bioeconomy 
Blueprint,7 World Technology Evaluation Center (WTEC),8 Department of Energy,9 and 
the Wilson Center10 have broadly addressed various challenges and opportunities in 
Engineering Biology. This report is a concise evaluation of translational technology 
opportunities that can accelerate the growth and vitality of the Engineering Biology 
community. 
  
                                            
5 The emphasis on “pre-competitive” is critical; individual companies are keenly focused on keeping their 
competitive advantage for their later-stage technology.  
6  National Research Council. Industrialization of Biology: A Roadmap to Accelerate the Advanced 
Manufacturing of Chemicals. Washington, DC: The National Academies Press, 2015. 
doi:10.17226/19001. 
7  Office of Science and Technology Policy. National Bioeconomy Blueprint. April 2012. 
https://www.whitehouse.gov/sites/default/files/microsites/ostp/national_bioeconomy_blueprint_april_2012.
pdf  
8 WTEC. Global Assessment of Biological Engineering & Manufacturing. World Technology Evaluation 
Center. July 2015. http://www.wtec.org/bem/docs/BEM-FinalReport-Web.pdf  
9  U.S. Department of Energy. Synthetic Biology: Report to Congress. July 2013. 
http://www.synberc.org/sites/default/files/DOE%20Synthetic%20Biology%20Report%20to%20Congress_
Fnl.pdf  
10 Drinkwater, K., Kuiken, T., Lightfoot, S., McNamara, J., & Oye, K. Creating a Research Agenda for the 
Ecological Implications of Synthetic Biology. Synthetic Biology Project, Wilson Center, and Massachusetts 
Institute of Technology, May 2014.  
http://www.synbioproject.org/process/assets/files/6685/_draft/synbio_res_agenda.pdf  
 
  
 
 
 
6 
ABOUT THIS REPORT 
The goal of this report is to identify translational platform technologies in Engineering 
Biology with cross-cutting appeal and the potential for co-investment by the private 
sector.  
Subject matter experts in Engineering Biology were asked to identify and prioritize 
emerging platform technologies, and to also address industry challenges related to 
intellectual property, technology transfer, regulation, and other topics. By recruiting the 
Panel Experts primarily from commercial companies, the perspective of industrial 
stakeholders in the field was captured. However, selected academics were included to 
offer a balanced range of views and opinions on key platform technologies that may be 
at an earlier stage of development. This report relies heavily on the inputs of Panel 
Experts in order to arrive at the recommendations. For more information about the 
Panel Experts, please see Appendix 1. 
This report is designed to be a short-duration assessment of technology opportunities 
and challenges germane to advanced manufacturing R&D, with a specific focus on 
translational R&D. Technologies are evaluated using a variety of criteria, including: 
• The potential for private sector co-investment,  
• Cross-cutting appeal/impact to industry, and  
• The likelihood that the technology (if matured) will give the U.S. a first-mover 
advantage in the marketplace. 
This report identifies four key translational and enabling technologies that are critical in 
the Design-Build-Test-Learn (DBTL) development cycle in Engineering Biology. These 
tools are likely to address some of the most significant barriers in the biomanufacturing 
industry. The key technologies identified here represent only a subset of possible 
solutions in the very broad and very dynamic field of Engineering Biology. A deeper dive 
into this topic could yield a more comprehensive set of solutions. 
The findings in this report were echoed in an Agile Biomanufacturing workshop 
sponsored by Department of Energy (DOE).11 This DOE workshop asked industrial 
stakeholders to identify and prioritize a common set of pre-competitive biomanufacturing 
tools that could be developed by a government-sponsored consortia. The ultimate goal 
is to develop shared development tools to speed the scale up/out process, thereby 
accelerating the bioeconomy in the process. The workshop confirmed that the 
                                            
11 The initial Agile Biomanufacturing Industry Listening Day was held on March 15, 2016, sponsored by 
Lawrence Berkeley National Laboratories, Berkeley, CA. Additional workshops are planned in 2016. 
http://agilebio.lbl.gov/home/industry-listening-day-march-15-2016/  
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development of standardized and tractable host organisms remains an elusive but 
potentially beneficial solution for the industry. The DOE workshop elaborated on the 
concept of host strains by emphasizing a focus on the development of “beachhead 
molecules” where defined “beachhead pathways” can be used to guide developers to 
specific molecules of interest in a particular host.  
Beyond the technology challenges, this report found that several other non-technical 
barriers exist that will continue to hamper the biomanufacturing industry if not 
addressed. The issue of regulatory barriers and the need for reform was repeatedly 
raised by the Panel Experts and this was also reiterated by other recent reports.12,13 
This report includes suggestions on how to address regulatory barriers, as well as other 
efforts and roles that the Federal Government can adopt to further the bioeconomy 
including co-investment in various technological, regulatory, and public education 
initiatives. Some of these areas overlap with those discussed in the 2012 report on the 
National Bioeconomy Blueprint.14 
Another element that differentiates this report from the other recent 
Synthetic/Engineering Biology reports is the inclusion of intellectual property (IP) and 
workforce development issues faced by the bioeconomy. Additionally, this report 
includes a section on international benchmarking, which identifies targets of opportunity 
that the U.S. can seek to to leverage.   
                                            
12 Carter, S. R., Rodemeyer, M., Garfinkel, M. S., Friedman, R. M. Synthetic Biology and the U.S. 
Biotechnology Regulatory System: Challenges and Options. J. Craig Venter Institute. May 2014. 
http://www.jcvi.org/cms/fileadmin/site/research/projects/synthetic-biology-and-the-us-regulatory-
system/full-report.pdf  
13 Bergeson, L. L., Campbell, L. M., et al. The DNA of the U.S. Regulatory System: Are We Getting It 
Right for Synthetic Biology? The Wilson Center: Synthetic Biology Project. October 2015. 
https://www.wilsoncenter.org/sites/default/files/synbio_reg_report_final.pdf  
14  Office of Science and Technology Policy. National Bioeconomy Blueprint. April 2012. 
https://www.whitehouse.gov/sites/default/files/microsites/ostp/national_bioeconomy_blueprint_april_2012.
pdf 
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IDENTIFYING TRANSLATIONAL TECHNOLOGIES 
Under an accelerated timeline of two months, the process illustrated by Figure 1 was 
used to identify the emerging technologies discussed in this report. 
1) A questionnaire was developed that covered a range of topics related to technical 
maturity, scale-up/scale-out of emerging platform technologies, private sector 
investment, regulations, technology transfer, workforce development, and 
international benchmarking. 
2) Based on recent academic, industry and government reports, a panel of national 
thought leaders in the field of Engineering Biology was assembled.  
3) The Panel Experts supplied detailed answers to the questionnaire to determine the 
emerging platform technologies that could meet the following criteria: 
o Cross-Cutting Appeal: The first criterion is to select those platform technologies 
in Engineering Biology that will be applied most broadly to the industry and also 
to the consumer. Cross-cutting appeal leads to a larger market potential, thereby 
generating a future economic benefit that warrants government investment. 
o Co-Investment Potential: The second criterion is whether private industry would 
be likely to co-invest with the Federal Government in the identified emerging 
platform technologies. The desire is to find platform technologies that are highly 
desirable, but not sufficiently mature to warrant purely private investment.  
The barriers facing these technologies were discussed, including (but not limited 
to) IP, technology transfer, regulations, and irregular funding patterns. Questions 
about economic impact, job growth, and the likelihood of the U.S. gaining a first-
mover advantage were also discussed. 
4) Data on early-stage technologies were refined and ranked according to the cross-
cutting and co-investment criteria above. Virtual roundtables were conducted to 
Figure 1: MForesight Process 
 
  
 
 
 
9 
understand the tradeoffs between different emerging technologies and to ultimately 
select those technologies that best meet the criteria above. 
5) Additional one-on-one phone interviews with Panel Experts were conducted to clarify 
some of the points raised at the roundtable and to seek more holistic responses on 
specific topics. 
SELECTION OF EMERGING TECHNOLOGIES 
The questionnaire asked the following: 
Please identify the promising platform technologies (both in manufacturing 
and in therapeutics) in your field that you feel will have the maximum 
impact in health outcomes and economic growth over the next 5-10 years. 
Table 1 provides a listing of seven emerging platform technologies identified in 
response to the question. 
 
These seven technologies represent a cross-section of topics in Engineering Biology 
with the greatest potential for improved health outcomes and economic growth. Each 
technology was then evaluated using the criteria of cross-cutting appeal and co-
investment potential. The degree to which a given technology would give the U.S. a 
first-mover advantage was also considered. 
 
A B C D E F G
1. Standardized, verified and tractable host cells or strains for scaled-
up biomanufacturing  X X X X
 2. High throughput omics including metabolomics, proteomics and 
metagenomics along with  bioinformatics and systems biology 
integration of the data X X X
3. Low cost and error-free DNA elements and DNA assembly X X  X X  
4. Protein and DNA screening kits of non-unique DNA signatures for 
QC, regulatory compliance and biosafety concerns. X X
5. Production of high value therapeutics in controlled environment 
plant systems X X
6. Efficient gene editing or modification technologies that are host-
neutral  X X X
7. Scaling out technologies; miniaturized fermenters and cell-free 
synthesis X X
Emerging Technologies in Engineering Biology
Panel Expert Poll
Table 1: Emerging Platform Technologies and Expert Poll Results 
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REFINING THE EMERGING TECHNOLOGY LIST 
Using the results from the Expert poll, the seven candidate technologies were reduced 
to one key platform technology and three enabling tools. 
 
Figure 2: A Range of Candidate Translational Technologies were reduced to a Key Platform 
Technology and Enabling Tools 
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SELECTED TRANSLATIONAL TECHNOLOGY & ENABLING TOOLS  
The results include one key translational technology and three enabling tools (see 
Figure 3). 
 
Figure 3: Translational Technologies That Can Be Applied Broadly Across the Engineering 
Biology Industry 
KEY TRANSLATIONAL PLATFORM TECHNOLOGY 
Standardized, Verified and Tractable Host Cells or Strains for Scaled-Up 
Biomanufacturing 
The issue of tractable host cells or strains was consistently supported. Currently, the 
development of new host cells and strains (hosts) is a slow and expensive process, so 
companies typically use existing, well characterized host cells or strains based on 
Escherichia coli (bacteria), Saccharomyces cerevisiae (yeast), and Chinese hamster 
ovary (CHO) cells (mammalian). Some of these host cells or strains are not well 
characterized. While it is expedient to use existing hosts, the scale-up process can yield 
unintended results.  
To gain more control of the scale-up process, individual companies are working 
independently to find solutions with desirable industrial scale properties. However, a 
standardized, well characterized, tractable set of hosts—applicable to the various 
application areas—would be highly beneficial for the industry as a whole. Ideally, the 
hosts would have beneficial characteristics such as high temperature tolerance and pH 
tolerance in order to support stable scaling to industrial production. Other measureable 
goals would be (for example) to increase the production yield of host cells by limiting 
repressor pathways and optimizing efflux pump pathways. A desired scenario would be 
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to have highly tractable hosts and robust measurement tools that quickly achieve the 
pathway modifications, leading to faster and more predictable outcomes.  
These issues can be addressed by developing an improved understanding of some of 
the more poorly characterized existing hosts or the development of new hosts. The 
recommended number of new hosts needed is not excessive; perhaps in the range of 
five or six. Hosts based on Pichia pastoris, Bacillus subtilis, Streptomyces are examples 
of hosts used in industry. Markets and reference hosts for Chinese hamster ovary 
(CHO) cells are another possibility.   
CHO cells actually refer to a very diverse 
set of cells that originated from a single 
CHO cell from the 1950s. One important 
feature of CHO cells is the ability to 
rapidly adapt to various environments 
and applications. This feature has led to 
the widespread use of CHO cells for 
manufacturing therapeutic proteins. 
However, the ability to rapidly evolve is 
believed to be a result of genomic 
instability. As a result, the CHO cells 
used by one company are very different 
from the CHO cells used by any other 
company, and are different than the 
CHO cells used in academic research. 
Each collection of these cells will have 
different performance characteristics, 
media and growth requirements, and 
productivity. 15  Moreover, even within a 
single company, CHO cells evolve over 
time resulting in "cell line instability" 
which creates a challenge: once a 
platform process is established, the cells may behave unexpectedly for no obvious 
                                            
15 A recent publication sequenced the genome of the CHO K1 cell (the most basic, standardized CHO 
cell). The team sequenced the cells from the ATCC collection (the 'standard reference collection in 
America') as well as ECACC (the European equivalent). The study identified hundreds of thousands of 
single nucleotide variants between what should have been identical genome sequences.  
Lewis N. E., Liu X., Li Y., et al. Genomic landscapes of Chinese hamster ovary cell lines as revealed by 
the Cricetulus griseus draft genome. Nat Biotechnol. 2013 Aug: 31(8):759-65. doi: 10.1038/nbt.2624. 
http://www.ncbi.nlm.nih.gov/pubmed/23873082 
DIFFERING PERSPECTIVES 
Based on the evidence that many companies 
prefer to work with hosts that they understand 
well to explore exotic pathways, there were 
some reservations about the value of 
developing new ‘exotic’ host strains. This is 
contrary to the suggestion that a single, fully 
synthetic host be supported, even though a 
minimal set of metabolic pathways might result 
in tractability and predictable modification of 
the host.   
Although the development of tractable hosts 
might suggest developing only microbial hosts, 
plant and mammalian “chassis” should not be 
ignored. For example, pigs have undergone 
initial genome editing to become optimized 
human organ donors. This form of 
biomanufacturing does not result in a 
chemically-based product, but nonetheless 
might also be considered a legitimate host. 
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reason. There is a need for the development of reference cells, reference cell culture 
media, reference proteins, and other related materials to streamline and accelerate 
production of therapeutic proteins, facilitate regulatory approval, and broaden the impact 
of research on CHO cells. 
Another approach, in addition to the development of standardized hosts, is to focus on 
developing standardized pathways to generate defined enzymes called “beachhead 
molecules.”16 Hosts might then be characterized by a tiered specification sheet that not 
only classifies hosts for certain culture conditions, but also for the production of certain 
beachhead molecules. Companies can then utilize these hosts and their defined 
“beachhead pathways” to further develop molecules of interest. The advantage with 
beachhead molecules is that the industry can readily retain intellectual property to any 
commercially viable molecule they develop, but the pathway to that molecule need not 
be fully developed from scratch. 
Managing the Host Strain 
One potential avenue for development is to create a PPP to develop new tractable 
hosts, with the characterized hosts made available in a national repository (potentially 
located at one of the national laboratories). This model would manage access to 
verified, standardized hosts in a controlled way. In addition, U.S. companies could focus 
on the hardening and commercialization of a new product rather than redundantly 
developing suitable host strains.  
A further advantage of the national repository model is the ability for regulatory agencies 
to be included from the start of host organism development. The resulting host 
organisms would be an entry point solution that is pre-vetted from a regulatory 
standpoint,17 which in turn would lower barriers for small and mid-sized companies to 
enter the market. This represents a democratization of the technology by creating new 
opportunities for innovation in all levels and segments of the bio-industry. 
The concept of managing host strains at the national laboratories was discussed with 
industrial stakeholders at the Agile Biomanufacturing workshop in March of 2015. The 
DOE already has substantial facilities based on their work to develop advanced 
                                            
16 This approach is advocated by Lawrence Berkeley Labs.  
17 An example of a successful pre-approval process can be found in the EPA MCAN § 725.420, where 
recipient microorganisms are listed that are eligible for the tiered exemption from review. The following 
recipient microorganisms are listed in MCAN § 725.420 as eligible for exemption under this subpart: 
(a) Acetobacter aceti. (b) Aspergillus niger, (c) Aspergillus oryzae. (d) Bacillus licheniformis. (e) Bacillus 
subtilis. (f) Clostridium acetobutylicum. (g) Escherichia coli K-12. (h) Penicillium roqueforti. (i) 
Saccharomyces cerevisiae. (j) Saccharomyces uvarum. https://www.gpo.gov/fdsys/pkg/CFR-2000-title40-
vol23/pdf/CFR-2000-title40-vol23-sec725-420.pdf  
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biofuels, renewable chemicals, and bioproducts. This invested capital can be further 
leveraged to manage any host strain developed, but mechanisms are still needed to 
resolve the challenges of intellectual property and cost. 
ENABLING TOOLS FOR HOST CELL DEVELOPMENT 
The following enabling tools are used by developers seeking to create new host cells or 
strains.  
High Throughput Omics Including Metabolomics, Proteomics and Metagenomics 
Along With Bioinformatics and Systems Biology Integration of the Data 
Current State: The tools and technologies currently used in determining pathway 
function and cellular physiology in Engineering Biology were co-opted from the omics 
field of the life sciences. However, the needs and challenges in the Design-Build-Test-
Learn loop of Engineering Biology necessitate the development of new tools and 
technologies for this space. These Engineering Biology specific omics tools would be 
used in the development and optimization of organisms for scale-up manufacturing. 
Concomitantly, the development of bioinformatics tools is also needed to effectively 
analyze the data acquired with the new 
omics tools.18 
Value Propositions & Impact: In both the 
design and verification stage of 
developing hosts, the Engineering 
Biology-specific omics developed will be 
relied upon to create and standardize 
these hosts. Without the development of 
these high throughput tools, the ability to 
fully characterize and screen hosts 
would be hampered, and would likely 
delay the development of hosts or efforts 
to standardize hosts. 
The combined Engineering Biology-
specific omics and bioinformatics tools 
and techniques would accelerate natural 
product discovery from metagenomes for 
small molecule therapeutics. This 
discovery paradigm can expand and 
                                            
18 An example: Smanski, M. J., Bhatia, S., et al. Functional optimization of gene clusters by combinatorial 
design and assembly. Nature Biotechnology. 2014 Nov.: 32, 1241-1249. doi: 10.1038/nbt.3063 
DIFFERING PERSPECTIVES 
Several Panel Experts felt that although 
sufficient omics tools were already on the 
market, the advantage of public-private 
partnerships would be the creation of open 
omics tools and ever-growing databases. These 
tools would be readily accessible by the public 
without IP barriers.   
Additionally, an emphasis on hardening and 
commercializing existing tools is needed. There 
is a large universe of exceptional tools already 
developed in academic settings. These tools 
simply require “last mile” completion to make 
them robust, fully documented, actively 
supported, and made available through open 
source platforms. 
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accelerate efforts that have otherwise become inefficient. This is especially important in 
the context of anti-infective therapeutics. 
In the Agile Biomanufacturing workshop, data sharing to avoid duplicating efforts was a 
key theme. Specifically, the advantages/disadvantages of a “push-pull” bioinformatics 
system were discussed. In the optimal system, a “push” system triggers a notification to 
an interested party when a certain enzyme had been developed. This is in contrast to a 
“pull” system where a given developer seeks to independently elucidate a pathway or 
develop a certain enzyme for their product. A push-based bioinformatics system would 
tie in well with the concept of developing beachhead molecules (open source 
intermediates) that companies can use to develop their own IP. Such a system can also 
incorporate Life Cycle Analysis and Technoeconomic Analysis to notify interested 
parties when favorable conditions have arisen. 
Value Proposition and Impact: Metagenomics would support the genomic analysis of 
large scale environmental samples to discover novel natural products, molecules, or 
enzymes for therapeutic and biotech applications. Additional development of 
bioinformatics will lead to the ability to process large amounts of sample data, ultimately 
probing the structure of mixed microbial communities. These technologies would have 
applicability in other relevant areas.  
Low Cost and Error-Free DNA Elements and DNA Assembly 
Current State: Oligonucleotide synthesis is the underlying method used in building 
complex DNA elements. Presently, oligonucleotide synthesis is still based on a 30 year- 
old phosphoramidite-based synthesis technique, and is a limiting factor in the 
progression of genetic engineering. The current price of DNA constructs is in the range 
of 10 to 30 or more cents per base, depending on quality, length, complexity, and yield. 
Interestingly, the industrial stakeholders in the Agile Biomanufacturing workshop had 
the opinion that the cost of DNA synthesis is not the limiting factor in their Build process. 
Instead, the industrial stakeholders desired rapid synthesis of gene constructs (in the 
range of 20 – 30kb) in weeks instead of months. That said, some industrial stakeholders 
believe that federal funding for the development of new (faster and cheaper) ways of 
DNA synthesis would lead to industry-wide benefits. 
Value Proposition and Impact: Lowering the cost and errors of DNA synthesis and 
assembly would allow a greater number of potential hosts to be evaluated for limits to 
genetic modification and pathway construction in a high throughput manner, and thus 
reduce host development timelines.  
 
  
 
 
 
16 
Additional reductions in cost would enable high throughput design and testing of novel 
organisms and genetic pathways. As a result, designers would see improved scale-up, 
improved hosts, and improved pathways. 
Lowering cost barriers would impact all 
sectors of Engineering Biology including 
metagenomics and host cell 
development.19 
Further development in DNA elements 
would also addresses a major limitation 
in oligonucleotide synthesis, which is the 
accumulation of errors in the sequences 
of long DNA elements. These errors 
arise during the oligonucleotide synthesis 
or during the assembly of these 
oligonucleotides into longer DNA 
elements. Elimination of these errors 
while keeping the costs down for these 
DNA elements would transform all areas 
of Engineering Biology. The expansion of 
the types of sequences which can be 
synthesized is also a needed area for 
development. For example, existing 
technologies are limited to a narrow 
nucleotide composition range which is 
limiting when using gram-positive host 
organisms. Development of improved high-GC synthesis, homopolymer runs, and 
transcriptional control elements (which often contain secondary structure) will be 
another key area of research that is needed to fully realize DNA synthesis impact and 
application.  
Desired Result: Ideally, additional development will result in low cost (below one-cent a 
base pair), high fidelity DNA constructs of lengths up to 50 kB.20  
                                            
19 An example: Zhou, H., Vonk, B., Roubos, J. A., Bovenberg, R. A. L., & Voigt, C. A. Algorithmic co-
optimization of genetic constructs and growth conditions: application to 6-ACA, a potential nylon-6 
precursor. Nucleic Acids Research. 2015 Dec: 43(21): 10560-10570. doi: 10.1093/nar/gkv1071 
20 The outcome technology might be oligos but the actual customer most likely will want to see double 
stranded DNA because it is a significant extra set of steps to assemble 20 kB from oligos. 
DIFFERING PERSPECTIVES 
Some believe that delivery of gene editing 
constructs as a human medical application is 
not a medical paradigm to be pursued, so 
development of zero off-target gene editing 
techniques would not be of value. Existing 
off-target effects are sufficiently addressable 
to yield safety and efficacy profiles 
comparable or better than the standard of 
care approaches now in medical practice.  
On the other hand, off-target effects are a 
significant issue when gene editing systems 
are delivered via plasmids and continuously 
expressed as in cell engineering studies. 
Additionally, studies in genome-wide 
functional screens with gene editing systems 
would be negatively impacted if the off-target 
effects are significant.  
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Efficient, Host Neutral Gene Editing Techniques 
Current State: Gene editing techniques allow the knock-in or knock-out of genes or 
genetic elements in an organism. The need exists for the ability to multiplex with the use 
of different guide sequences as most disease states are multi-factorial from a genetic 
standpoint.  
Value Proposition and Impact: In the development of host cells or strains, site-specific 
insertion, mutation, and deletion of genes is likely necessary, and new gene editing 
techniques would enable these tasks to be done efficiently and with low error rates. 
With the development of precise and efficient gene editing tools, the design cycles and 
timelines for host development will be significantly reduced.   
Gene editing has the potential to play a significant impact in the healthcare sector 
through human gene therapy. Treatment of genetic diseases might be accomplished 
through inactivating genes, repairing mutations, or introducing other genes. Gene 
editing is also influencing the biomanufacturing industry by enabling the genetic 
modification of host strains to produce novel metabolites through exotic pathways. The 
approaches to gene editing have primarily involved nucleases to cleave the genome at 
specific sites. These nucleases include zinc-finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs) and CRISPR/Cas9. Newer CRISPR-based 
or RNA-guided nucleases, such as Cpf1, will make gene editing more efficient. 
OTHER OPPORTUNITIES 
The remaining technologies in Table 1 did not fully meet the cross-cutting/co-investment 
criteria. For completeness, a brief description is provided for the remaining emerging 
technologies along with comments on each. 
SCALED-UP, COST-EFFECTIVE PROTEIN OR RNA PRODUCTION FOR AGRICULTURAL-SPECIFIC 
DIAGNOSTICS 
In the agricultural industry, one area that is impacting the late stage registration of a 
transgenic plant is the scaled-up manufacturing of protein or RNA for regulatory use. 
These analyte test materials are required to establish safety profiles through various 
toxicology studies and the amount required is beyond the scaling-up capabilities of a 
typical agricultural company. Existing solutions for scaling up analyte test material 
production are borrowed from pharmaceutical product scale-up, thus making them 
unsuitable for agricultural applications in terms of cost, timelines, and lack of actual 
upstream development (unlike optimization of the genes for expression in fermentation, 
an agricultural company is more interested in optimization of a crop plant). A negative 
consequence may be that someone approaches a third party who may assume some 
initial work has been completed. If it has not, the timeline extends and costs either go up 
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or they simply cannot do it. Development of agricultural focused technologies to scale 
up the production of these analytes in a reliable and cost-effective manner would 
accelerate the regulatory process and the eventual commercialization of the product.  
Comment: This technology was likely not selected due to the narrow impact.  
PROTEIN & DNA SCREENING KITS OF TRANSGENICS WITH NON-UNIQUE DNA SIGNATURES FOR 
QC, REGULATORY COMPLIANCE & BIOSAFETY CONCERNS 
This platform technology addresses anticipated, future concerns in the agricultural 
industry, particularly in the management of compliance and quality control (QC) of 
transgenic plants. Screening kits to detect the protein and DNA of inserted genes are 
required to ensure import or export compliance of transgenic plants, and to prevent 
unregistered transgenic plants from being distributed (thus ensuring international 
competitiveness). Existing screening kits have been developed to utilize the unique 
DNA signatures that arise from random insertions of genes into the plant which 
determines lot specificity of the transgenic plant (in the parlance, the regulated event). 
Advances in gene editing technologies allowing the insertion of transgenes into a 
genome at specific locations with repeatability will theoretically remove this advantage 
of random insertions that serve to determine lot event specificity with the diagnostics. 
Thus, novel methods for screening protein and DNA of transgenes developed using 
these new gene editing tools are needed to address QC, regulatory lifespans, and 
biosafety concerns.  
Comment: The limited applicability of this technology to other sectors of Engineering 
Biology did not elicit a large number of votes.   
SCALING OUT TECHNOLOGIES: MINIATURIZED FERMENTERS AND CELL-FREE SYNTHESIS 
The traditional production of therapeutics using bacterial or mammalian cells will reach 
the limits of their production capacity in the near future. Transgenic plants have been 
developed as an alternative to address this limitation in therapeutic production and the 
lower cost of production and expansion with transgenic plants may provide this 
technology with a cost advantage over traditional production systems. However, 
transgenic plants need to be cultivated in controlled environments and this requirement 
can potentially increase the cost of production. Pharmaceuticals produced in plants 
range from antibodies to vaccines. Some plant-made pharmaceuticals are in clinical 
trials and many more are in other stages of development. For instance, a patient with 
Ebola was treated in part by a protein therapeutic produced in a plant.21 
                                            
21 PBS NewsHour. How to grow an Ebola vaccine with a tobacco plant. 2015.  
http://www.pbs.org/newshour/bb/how-to-grow-an-ebola-vaccine-with-a-tobacco-plant/ 
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Comment: The issue of scaling up miniaturized fermenters was discussed at length 
during the virtual roundtable and also with a one-on-one phone call with a Panel Expert. 
This is an example of the so-called common correlation problem, where assays on 
microtiter plates do not accurately scale to commodity-scale 200 liter fermenters. This is 
a substantial barrier and many companies are individually seeking to address the 
problem by investigating fundamental parameters such as temperature maintenance or 
oxygen transfer rates. If this barrier were to be removed, the pace of technology scale-
out would be increased and more products could move towards commercial viability.   
BROADER CHALLENGES AND THE ROLE OF THE FEDERAL 
GOVERNMENT  
Certain factors have contributed to market failures among Engineering Biology 
ventures. Primary barriers for investment include technical risk, an uncertain regulatory 
climate, and undefined market opportunities that limit private investment.  
DE-RISKING & TECHNOLOGY DEVELOPMENT 
Government co-investment is seen as necessary to de-risk any nascent platform 
technology. A number of examples show how government co-investment can result in a 
successful product, e.g. the development of the anti-malarial drug Artemisinin by UC 
Berkeley and its commercialization by Amyris and Sanofi.22 
Platform technologies can be significantly de-risked if all the stakeholders are involved 
in their development through a consortium-like arrangement. This is the approach 
advocated by the Department of Energy, where federal labs will leverage existing 
resources to develop pre-competitive tools for industry.    
There is a need to keep the pre-competitive and core technology development as open 
as possible. Open collaboration is based on the use of standard biological platforms, 
data systems, and testing/manufacturing standards. Openness allows the powerful 
development of such standards, and populates the academic and industrial 
environments with enough common technology to accelerate research.  
A key advantage of the open consortia model is that it hedges against a narrow or 
specialized agenda for the foundational platforms, instead yielding technologies that are 
beyond company-specific inventions. Potential consortia models that could be replicated 
include the NSF-funded Synberc (Synthetic Biology Research Center),23 and the follow-
                                            
22  Sanders, R. Launch of antimalarial drug a triumph for UC Berkeley, synthetic biology. 2013. 
http://news.berkeley.edu/2013/04/11/launch-of-antimalarial-drug-a-triumph-for-uc-berkeley-synthetic-
biology/ 
23 http://www.synberc.org 
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on EBRC (Engineering Biology Research Consortium),24 now under development. It 
was noted that Synberc has been effective in bringing together academics and industry 
folks in partnerships where industry can—for relatively low cost—observe and co-design 
longer-term investment or high-risk science and technology. Industry and academia 
appreciate opportunities for close collaboration in such co-development, which 
ultimately accelerates the development and implementation of related intellectual 
property. 
While government co-investment can, in general, de-risk technology development, 
current aspects of the regulatory environment can make commercialization and end-
user acceptance difficult. Government should also understand how to de-risk 
technology commercialization, especially given the anti-GMO sentiment in the public 
today. Science-based advocacy is the best approach to inform the public. 
On the topic of therapeutics for humans, there is difficulty with conducting risk 
assessment owing to several unknowns, such as the jump from animal models to 
humans, thereby lessening the predictive value of early-stage data. Also, the FDA and 
insurance payers have continually shifting requirements, and the technological progress 
of competitors is hard to predict. Furthermore, the huge cost of clinical trials and the 
need for substantial human data prior to investment in definitive clinical trials has 
caused investors to shy away from smaller markets. This has put a burden on the 
government to bridge the gap between animal models and exploratory human studies.   
One Panel Expert stated: “This has also created interest in developing flexible research 
platforms for exploratory clinical research to better understand the biology as it pertains 
to the heterogeneous human population, and to help define the most simple and reliable 
system that can be manufactured at a price-point for sustainable commercial 
dissemination, given insurance reimbursement. This research platform is notably more 
complex than what the final product will be and is therefore much more costly and less 
scalable, but it has become a critical necessity to obtain human data to better define the 
eventual medical device product.” 
Other potential public and private funding model examples include the NIH SPARC 
Program ($248M pending available funding),25 the NIH BRAIN Initiative (projected $4.5 
billion through 2025),26 the DARPA ElectRx, SUBNETS, and RAM Programs27 ($78.9M, 
                                            
24 http://www.synberc.org/ebrc 
25 Bioelectronics SPARC at NIH. Nature Biotechnology, 32: 855. 2014. doi:10.1038/nbt0914-855b  
26 National Institutes of Health. NIH embraces bold, 12-year scientific vision for BRAIN Initiative. 2014 
Jun. 5. https://www.nih.gov/news-events/news-releases/nih-embraces-bold-12-year-scientific-vision-brain-
initiative  
27 DARPA. DARPA and the BRAIN Initiative. http://www.darpa.mil/program/our-research/darpa-and-the-
brain-initiative  
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$70M, and $40M respectively, pending available funding), and the GlaxoSmithKline 
Bioelectronic Medicines efforts (over $50M). 28  The European Union has recently 
announced a similar effort to the NIH SPARC Program in scope and scale (FET 
Proactive, Topic: Intra- and inter-cell bio-technologies). 29  Although each of these 
funding efforts differs in terms of a) focus on underlying biology, b) therapeutic 
indications considered, c) stage of development of projects solicited, and d) 
fundamental tolerance for risk, these programs are designed to push the boundaries of 
what is currently known about current Engineering Biology technology. Taxpayer 
investment is justified by the unique promise of Engineering Biology therapies (as 
shown in clinical results) and the previously mentioned regulatory drivers that require 
government support due to unknowns in the business case. As the technology matures, 
venture capital and industry investment in translational technologies becomes more 
viable.    
A major risk for Engineering Biology is the high degree of complexity for scaling-up and 
process development. This complexity is often overlooked in the development of new 
biological processes, especially those developed at universities. To fully manage 
development risk, developers need a good understanding how an organism will behave 
in production conditions, what separations are needed, and what fouling agents or 
contaminants can be carried through the process. That risk can be effectively mitigated 
by applying predictive scaling techniques and also by using downstream processing 
conditions to inform organism design. These are critical aspects of de-risking 
technologies for industrial adoption. 
REGULATORY REFORM 
The optimum regulatory approach is to implement a science-based framework that 
anticipates the rapid pace of technological development. This approach would be highly 
beneficial to the industry as a whole, enabling the U.S. to be more competitive 
internationally. Admittedly, regulatory challenges stem in part from the rapid pace of 
change in the Engineering Biology industry. 30 Currently, the FDA categorizes products 
by the primary mode of action (21CFR3.2(k)) which is either chemical (CBER/CDER) or 
physical (CDRH). The Office of Combination Products (OCP) spans and bridges centers 
within the FDA, coordinating the review of any combination products that consist of two 
                                            
28 GSK. Bioelectronics R&D. http://www.gsk.com/en-gb/partnerships/bioelectronics-research-network/  
29  European Commission. FET Proactive. https://ec.europa.eu/programmes/horizon2020/en/h2020-
section/fet-proactive  
30 Bergeson, L. L., Campbell, L. M., et al. The DNA of the U.S. Regulatory System: Are We Getting It 
Right for Synthetic Biology? The Wilson Center: Synthetic Biology Project. October 2015. 
https://www.wilsoncenter.org/sites/default/files/synbio_reg_report_final.pdf 
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or more regulated components (biological products and a device).31 As an example, a 
biological product packaged with a delivery device would fall under this definition.32  
Recent public outreach meetings in 2015/2016 coordinated by the Office of Science and 
Technology Policy (OSTP) have occurred in order to review progress made on efforts to 
modernize the regulatory system for biotechnology products.33 This positive action is 
part of an overall effort to modernize the regulatory system for biotechnology products, 
and seeks to clearly identify roles and responsibilities of the EPA, FDA, and USDA 
regarding biotechnology products.  
The following suggestions are offered to increase the speed and predictability of 
regulatory processes: 
• Embed (more) technology experts in regulatory agencies to enhance and 
accelerate guidance. 
The FDA has become much more proactive in recent years by creating a 
partnership in innovation. The result has been beneficial for the industry and 
continued efforts are strongly encouraged. Additional resources could be routed 
to regulatory agencies in order to hire the additional expertise needed to evaluate 
next-generation technologies in this rapidly growing and fast-moving field.   
Early stakeholder engagement was also identified as a critical component for 
improved regulations. For example, a regulatory (inter)agency consultation 
process could be established that provides incentives for engagement early in 
the development of the intended product. Leveraging the Pre-Submission 
Program may be one avenue for companies, academics, and others with 
510(k)s34 or appropriate performance testing to obtain FDA feedback prior to the 
submission of the marketing application. Regulatory bodies may consider 
including subject matter experts in these Pre-Submission meetings. A Pre-
Submission (Pre-Sub) is appropriate when FDA’s feedback on specific questions 
is necessary to guide product development and/or application preparation. The 
                                            
31 http://www.fda.gov/CombinationProducts/default.htm  
32 http://www.fda.gov/CombinationProducts/AboutCombinationProducts/ucm101496.htm  
33  Several public meeting have been held to receive public comment regarding the memorandum 
“Modernizing the Regulatory System for Biotechnology Products,” issued by the Executive Office of the 
President (EOP) in July 2015. These meetings were organized by OSTP (contact Robbie Barbero, Ph.D.). 
Documents regarding this outreach can be downloaded under “Coordinated Framework for the 
Regulation of Biotechnology and Developing a Long-Term Strategy for the Regulation of the Products of 
Biotechnology.” https://www.regulations.gov/#!docketDetail;D=FDA-2015-N-3403 
34http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/biotechnology/  
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FDA has streamlined the process by creating guidance documents to help an 
inventor or innovator submit a formal written request to the FDA for feedback.35  
The FDA has been proactive and open to innovators asking for either a formal 
written response, a meeting, or a teleconference to address concerns, questions, 
etc. The FDA recommends that innovators engage with The Center for Biologics 
Evaluation and Research (CBER), and may consider a similar policy requesting a 
Pre-Submission no less than 90 days prior to the submission of the pre-market 
application. Through the Pre-Submission Program, innovators may interact 
directly with the appropriate review branch.36 There is no user fee associated 
with the Pre-Submission Program, which helps encourage early engagement 
from startups and early stage innovators.  
• Increase coordination between multiple agencies to encourage new efficiencies.  
In cases where multiple agencies are required to assess the technology (such as 
genetically modified crops for food), the lead agency (acting as point of contact) 
needs to be identified promptly, with supporting agency roles clarified. For 
maximum efficiency, reviews should run in parallel (rather than serially) to 
provide guidance. 
• Establish a science-based biosafety regulatory policy.  
A strategic plan for new biotechnologies is strongly recommended, based on 
independent (non-industry specific) research objectives. External third party 
entities (such as university or government institutions) are best suited to develop 
this plan and validate the safety and efficacy of a proven technology. A regulatory 
process developed through the collaborative efforts of federal agencies and 
academics will likely yield a more objective, evidence-based method for 
evaluating products and future innovations.  
Currently, receiving approval for modified micro-organisms is highly heterogeneous and 
for some applications it can take as long as the development of the original organism. 
By adopting the recommendations above, approval times may be reduced. 
                                            
35 “Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings 
with Food and Drug Administration Staff” 
http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UC
M311176.pdf 
36http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHOffices
/ucm127854.htm 
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PRIVATE INVESTMENT 
Investors typically seek opportunities where a sector is continually growing and the 
technology has potential to have applicability across multiple sectors. Typical 
investment metrics include a desire to see at least a 20% price reduction compared to 
an existing product and at least a 5x to 10x improvement in performance to an existing 
product. Because of the long time frame for Engineering Biology technology to result in 
new therapies (and therefore realize economic value), the industry model includes some 
level of government investment to offset the long horizon. 
Some private investment in Engineering Biology has taken place in areas like early 
tools, and collaborative investment by public/private entities has taken place in newer 
platform technology startups. If regulatory agencies were to be involved early in the 
drug approval process, the private sector would be more likely to participate. Closer 
collaboration with regulators would keep the companies focused on their core activities, 
which increases the appeal to private investors.   
There is also a lack of standards and reference materials, as well as flexible and clear 
regulations. Clear regulations would result in well-defined platform technologies that 
have a “regulatory advantage.” These technologies may, in turn, end up as industry 
standards and references due to their clearly defined use profiles, rather than their 
quality. 
BARRIERS WITH TECHNOLOGY TRANSFER & INTELLECTUAL PROPERTY 
There are a number of barriers in transferring technology from academia to the 
marketplace.  
• Many academic institutions’ technology transfer offices do not understand the 
complexities of maturing a technology into a market-ready state, causing an 
overvaluation of early-stage discoveries. The academic community is typically 
unfamiliar with the level of non-clinical testing and manufacturing that is 
necessary to transition a product from proof-of-concept in the lab to exploratory 
clinical research. Bringing a product to market is a multi-step process involving 
regulatory compliance, marketing strategies, and (ultimately) operation within the 
Good Manufacturing Practices (GMP) regime. Technology transfer offices need 
additional seasoned staff and experience to correctly account for these 
development factors.    
• While it is well known that a funding gap exists for transitioning a technology from 
basic science to the development stage, the continuity of funding remains a 
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problem.37 Some options such as Small Business Technology Transfer (STTR) 
exist to continue development work, but the relative funding level for this program 
is much smaller than the Small Business Innovation Research (SBIR) program 
(which, admittedly, requires the creation of a startup company). 
• Experts also described the tension between the goals of academics and 
technology transfer personnel. Academics typically work in a collaborative 
commons-style fashion where ideas are freely shared and advances are built on 
the results from multiple colleagues. Conversely, staff at the technology transfer 
offices sometimes seek to constrain access to technology via IP claims, which 
allows a university to earn revenue via well-defined licensing agreements. This 
issue is compounded when a consortium, such as Synberc, fuses the work of 
multiple investigators and multiple universities. In this case, any industry person 
interested in acquiring a license may be challenged to even find the right person 
and/or institution to discuss the technology and negotiate the terms for using a 
technology. 
• Technology development could be accelerated through collaboration with 
academic institutions and national laboratories. However, accessing academic or 
national laboratories expertise and conducting benchtop, pre-clinical, or clinical 
testing is often out of reach; time- and budget-constrained innovators and 
startups often cannot afford to pay the direct and indirect costs associated with 
external validation testing.   
Government can play a key role in accelerating technology development by: 1) 
Making government funding available to help innovators and startups access 
academic and national laboratories resources such as clinical faculty expertise 
and laboratory equipment/testing services, and 2) Allowing funds to cover a 
larger fraction of indirect costs so that startups and innovators may apply funding 
directly to necessary technology validation.  
• A current concern is that a “patent-centric” approach to IP for Engineering 
Biology may be ill-suited to the needs of synthetic biology and synthetic biology 
companies.38 The concept of an “open source DNA” is a very powerful antidote to 
the current restrictive licenses, especially for translational platform technologies. 
Current open source models from software are already being modified to fit 
                                            
37 Ford, J. C. Federal Government’s Role in Tech Transfer Innovation. 2014 Nov. 4.  
http://www.nist.gov/director/upload/ford_Lab-to-Market_NIST.pdf  
38 Holman, C. M. Developments in Synthetic Biology are Altering the IP Imperatives of Biotechnology 
(2015). Vanderbilt J. Ent. & Tech. L. 17(2): 385-462. http://ssrn.com/abstract=2623153  
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biotechnology.39 Government can play an important role by bringing resources to 
a public-private partnership with industry and advocacy groups to clarify potential 
open models suitable for biotechnology.   
• Engineering Biology advances and developments can be hindered by negative 
publicity and resistance from consumer groups. For example, the public has 
shown “strong resistance” to genetically-manipulated salmon from the company 
AquaBounty (who produce a salmon which can grow to market size in half the 
time). 40  A number of companies have had to deal with negative press and 
complaints from advocacy groups against genomic-based products for consumer 
use.41,42 This has been identified as a serious barrier that must be addressed. 
There is potential to curtail and shift public opinion with the creation of science-
based advocacy and consumer education initiatives.  
WORKFORCE DEVELOPMENT 
New graduates entering the Engineering Biology field are not always well matched to 
the current job requirements. This is due to a variety of reasons: 
a) Academic faculty typically do not have expertise in commercialization, and instead 
focus on teaching the technical fundamentals of engineering to students. As a result, 
new employees at biotechnology firms can require significant time (up to 2 years) to 
gain an understanding of core concepts such as Design Controls and Quality 
Systems, Good Laboratory Practices (GLP), and Good Manufacturing Practices 
(GMP) for regulatory approval. 
b) Biotechnology companies are having difficulty creating clear distinctions between a 
career as a technologist and a career as a scientist. Entry-level positions for a 
technologist usually require a bachelor’s degree, but the skills at this level often 
include the use of complex instrumentation, computational/analytic tasks, and 
experience with software programming and instrumentation complexity. The difficulty 
and diversity of tasks exceeds the “technician” designation.  
c) Additional training to master the tasks in (b) can be found in graduate programs, but 
the reality is that funding for graduate students in the field of biotechnology has not 
                                            
39 BiOS, http://www.bios.net/; BioBricks Foundation, http://biobricks.org/  
40 Zhou, J. Despite Consumer Resistance, FDA Approves Salmon as First GMO Animal Fit for Food 
Supply. Epoch Times. 2015 Nov 23. http://www.theepochtimes.com/n3/1903295-salmon-approved-by-
fda-as-first-gmo-animal-fit-for-food-supply/  
41 Strom, S. Companies Quietly Apply Biofuel Tools to Household Products. The New York Times. 2014 
May 30. http://www.nytimes.com/2014/05/31/business/biofuel-tools-applied-to-household-soaps.html  
42  Colwell, K. Non-GMO Project says no to synthetic biology. 2015 Jun. 15. Friends of the Earth. 
http://www.foe.org/news/news-releases/2015-06-non-gmo-project-says-no-to-synthetic-biology  
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been adequate. As a result, graduate students are being trained in related areas 
(e.g. stem cell biology) that do not align well with current industry needs.  
Opportunities for improvement in workforce training include: 
• An expansion of certificate programs in high schools that result in entry level 
employees qualified to work in an Engineering Biology or molecular biology 
laboratory. 
• An expansion of programs like the Cold Spring Harbor Synthetic Biology summer 
course43 would be invaluable. 
• Better alignment of federal investment in research fellowships to the basic 
technology needs of the current industry. 
• Academic faculty integrating more industry development process concepts (GLP, 
GMP, etc.) into the engineering curriculum. Ideally, professors would have 
experience working in industry or they could bring in experts with regulatory and 
commercialization experience to supplement instruction.  
• Internships that expose students to industry-grade tooling. 
PARTNERSHIP MODELS 
These are opportunities for strategic partnerships: 
• Engineering Biology firms can partner with specialized engineering firms who are 
devoted to the “last mile” of development needed to commercialize a product. 
This mimics the model used by hardware engineering firms to complete the 
commercialization process, and is a straightforward, simple partnership. 
• Multiple academic institutions can partner to support research centers such as 
Synberc, which build the foundational tools and technologies for Engineering 
Biology. Synberc also provides a training ground for young researchers and 
engages with policymakers to advance the field of Engineering Biology. 
Research centers should encourage regulators to actively participate by 
previewing new technologies and working with industry to define appropriate 
application of those technologies. 
• Academic institutions can encourage collaboration between academic 
researchers and entrepreneurs by supporting startup accelerators. Many of these 
startups are funded by SBIR/STTR. Federal support of such accelerators would 
enhance collaboration. 
                                            
43 https://cshlsynbio.wordpress.com  
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• A formal pre-competitive consortium based on the NNMI model44  is another 
possible partnership. Academic institutions and industry could collaborate using 
the NNMI manufacturing research infrastructure to solve pre-competitive 
predictable scaling and process development challenges. Advances in these two 
areas would be transformative. The challenge is to identify companies with 
similar motivations and appropriate resources to apply to the NNMI model. 
• The proposed biomanufacturing consortium centered in the DOE’s national labs 
is yet another potential model. This approach has the advantage in that it brings 
substantial capital and the expertise of DOE national lab personnel who have 
diverse, project-based experience in feedstocks and bioproducts. But this 
approach is also challenged by industry’s perception (whether true or not) that 
working with the national labs may require longer timelines and higher fees. 
INTERNATIONAL BENCHMARKING 
U.S. COMPARATIVE ADVANTAGES/DISADVANTAGES  
The U.S. currently has the advantage of inheriting the scientific expertise from the 
biological/biotech revolution and by having funding mechanisms (SBIR/STTR) to 
support the commercialization of research in this area. In addition, U.S.-based venture 
capitalists are quite active in Engineering Biology and are tolerant to the inherent risks 
in this industry. They are also willing to invest substantially more money into 
commercializing a technology as compared to their counterparts in Europe. 
It was noted that the U.S. does not have a roadmap or national strategy in the area of 
Engineering Biology to help identify sectors for investment. A more comprehensive 
roadmap, similar to that drawn up by the Engineering Biology community in the UK, 
would spur the growth of the bioeconomy. 45  The National Academies of Sciences 
(NAS),46 OSTP Bioeconomy Blueprint,47 the Department of Energy,48 and the Wilson 
                                            
44 The National Network for Manufacturing Innovation. https://www.manufacturing.gov/nnmi/  
45  Research Councils UK. A Synthetic Biology Roadmap for the UK. July 2012. 
http://www.rcuk.ac.uk/publications/reports/syntheticbiologyroadmap/ 
46 Industrialization of Biology: A Roadmap to Accelerate the Advanced Manufacturing of Chemicals. 
National Research Council. 2015. http://www.nap.edu/catalog/19001/industrialization-of-biology-a-
roadmap-to-accelerate-the-advanced-manufacturing  
47  Office of Science and Technology Policy. National Bioeconomy Blueprint. April 2012. 
https://www.whitehouse.gov/sites/default/files/microsites/ostp/national_bioeconomy_blueprint_april_2012.
pdf  
48  U.S. Department of Energy. Synthetic Biology: Report to Congress. July 2013. 
http://www.synberc.org/sites/default/files/DOE%20Synthetic%20Biology%20Report%20to%20Congress_
Fnl.pdf  
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Center49—among others—have addressed various challenges and opportunities, with 
the NAS focusing on a roadmap for the advanced manufacturing of chemicals. The 
focus of the NAS roadmap is narrower and more defined in that it covers the production 
of chemicals rather than Engineering Biology.  
The cost and breadth of the regulatory approval process is deemed a disadvantage 
compared to the regulatory process in other countries. There are also differences in 
how the IP resulting from academic research is managed globally compared to the U.S. 
The governments of other countries tend to shoulder a larger financial stake in public-
private collaborations.  
UNIQUE U.S. ADVANTAGES TO LEVERAGE 
In order for the U.S. to gain maximum leverage in Engineering Biology, the following 
suggestions may be useful:   
1) The U.S. government should invest in a consortium(s) and advanced research 
hubs where all the players in the entire product development phase can 
collaborate to bring a product to market.  
2) NIST, federal regulators and academic leaders should work together to establish 
relevant standards in fields of Cell Biology and Engineering Biology. This same 
group should also work to establish a science-based biosafety regulatory policy. 
3) Because the U.S. operates under the non-precautionary principle (unlike the 
European Union), it is well poised to develop science-based policy regarding the 
safety of the uncontained release of GMOs. This is a substantial advantage and 
has the potential for high economic impact if maintained.  
SUMMARY 
This report identifies Standardized Verified and Tractable Host Cells or Strains for 
Biomanufacturing as the key platform technology that will most benefit the engineering 
biology community. By creating a standardized and verified host strain, the overall 
biomanufacturing process will be de-risked and streamlined. 
Additional development work on three enabling tools is needed to fully realize the 
potential offered by tractable host cells or strains. These tools are: (i) High Throughput 
Omics; (ii) Low-Cost and Error Free DNA Elements and DNA Assembly; and (iii) 
Efficient, Host-Neutral Gene Editing. The successful deployment of this technology suite 
                                            
49 Drinkwater, K., Kuiken, T., Lightfoot, S., McNamara, J., & Oye, K. Creating a Research Agenda for the 
Ecological Implications of Synthetic Biology. Synthetic Biology Project, Wilson Center, and Massachusetts 
Institute of Technology, May 2014.  
http://www.synbioproject.org/process/assets/files/6685/_draft/synbio_res_agenda.pdf  
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will enable more rapid Design-Build-Test-Learn (DBTL) cycles during product 
development.   
Overall, the unencumbered access to tractable hosts could be an important part of a 
“national tool box” where government and industry collaborate to develop pre-
competitive technologies in Engineering Biology. These technologies, along with 
appropriate regulations, will democratize the Engineering Biology industry, creating new 
opportunities and innovation from all levels and segments of the bio-industry.  
 
  
 
 
 
31 
APPENDIX 1: PANEL EXPERTS 
Panel Experts were assembled from industry, academic institutions, relevant NSF 
Engineering Research Centers, national laboratories, and individuals from NIST’s 
Advanced Manufacturing Technology Consortia program. The selected Panel Experts 
are acknowledged national thought-leaders in the key areas of agriculture, therapeutics, 
and natural products, and as such, their perspective is based on their primary fields-of-
experience. However, the Panel Experts were diligent in taking a broader view when 
discussing the industry. As a result, the platform technologies identified in this report 
can readily find applications in diverse areas ranging from biomass conversion to 
energy, chemicals, and polymer products. 
This report would not have been possible without the enthusiastic and dedicated 
participation of our Engineering Biology Panel Experts. During the course of the effort, 
the authors had the pleasure of personal communications with each Panel Expert, 
receiving valuable information on the topic. Whether by email, or in personal phone 
calls, each and every request by our team was answered promptly and completely. The 
authors gratefully acknowledge their participation in the creation of this report.  
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APPENDIX 2: INITIAL PROJECT GUIDANCE & RESOURCES 
QUESTIONS 
1. Advanced manufacturing technologies/processes 
a. For emerging industries, are there lessons they have learned in 
innovating new techniques when traditional manufacturing methods do 
not apply? 
b. What insights from traditional manufacturing might help this nascent 
industry (i.e., scaling up and/or scaling out for regenerative medicine) 
avoid potential problems ?   
c. Are there unique features from the regulatory process for medical 
products?   
d. What are the implications for industry in the unique business 
environment of "price controls" for medical treatments, a world in which 
the payers and the consumers are usually different? 
2. Industry investment 
a. What do investors (VCs, forward-leaning companies, etc.) want (i.e., 
what are they waiting for to make an investment)?  
b. How will emerging biotechnology platforms be de-risked sufficiently for 
industry to commercialize?   
c. There has already been significant activity addressing regulatory 
barriers and well as environmental risk/ impact – therefore it will be 
important to address this question in light of those public studies (out of 
JCVI and the Wilson Center in the area of synthetic biology) such that 
MForesight provides new insight to this question. 
3. Technology transfer 
a. What are the barriers to technology transfer from academia to industry 
for these specific fields? Economic, technology, policy, legal, capital 
expenditure, governance, etc.? 
4. Partnerships 
a. In what ways can these fields achieve strategic partnership?  
b. What types of industry/academic or public/ private partnerships might 
be successful to move basic research and largely public investments into 
these research areas into higher TRL endeavors that will more directly 
lead to commercialization?  
5. International benchmarking 
a. What are the strengths of the US capabilities of commercializing 
biologics? And how does this impact the national and global economy?  
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b. How will U.S. lead the way, rather than competing at the same 
ballgame?  
c. Are there growing competitive disadvantages from which we may never 
catch up? 
BIBLIOGRAPHY OF EXISTING SOURCES 
• NAS, Industrialization of Biology (link)  
• WTEC, International Assessment of Research on Biological Engineering & 
Manufacturing (link) 
• Research Councils UK, A Synthetic Biology Roadmap for the UK (link) 
• Wilson Center, Creating a Research Agenda for the Ecological Implications of 
Synthetic Biology (link) 
• JCVI, Synthetic Biology and the US Biotechnology Regulatory System (link) 
• DOE, Synthetic Biology: Report to Congress (link) 
• OSTP, Bioeconomy Blueprint (link) 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
www.mforesight.org 
 
